March 14, 2024

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

September 12, 2023

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

September 06, 2023

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 01, 2023

Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

June 08, 2023

Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

May 23, 2023

Protalix BioTherapeutics set to join Russell 3000® Index

May 18, 2023

Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

May 10, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

May 05, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

February 27, 2023

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

February 24, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease

February 21, 2023

Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023

February 21, 2023

Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023

December 04, 2022

Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102

November 14, 2022

Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results

September 06, 2022

Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 15, 2022

Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results

August 08, 2022

Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022

June 30, 2022

Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors

May 26, 2022

Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease

May 16, 2022

Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results

May 09, 2022

Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022

April 04, 2022

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease

March 31, 2022

Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results

March 24, 2022

Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022

March 18, 2022

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease

February 03, 2022

Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022

December 22, 2021

Protalix BioTherapeutics Issues 2021 Letter to Stockholders

November 15, 2021

Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update

November 08, 2021

Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021

October 15, 2021

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease

October 11, 2021

Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease

August 26, 2021

Protalix BioTherapeutics Announces Closing of Private Note Exchange

August 16, 2021

Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update

August 13, 2021

Protalix BioTherapeutics Announces Private Note Exchange

August 09, 2021

Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021

August 02, 2021

Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA

June 28, 2021

Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021

June 02, 2021

Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease

May 14, 2021

Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update

May 07, 2021

Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021

April 28, 2021

Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA

April 28, 2021

Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA

March 30, 2021

Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results

March 22, 2021

Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021

March 04, 2021

Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

February 23, 2021

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease

February 18, 2021

Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds

February 11, 2021

Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock

February 11, 2021

Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery